Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.

Inclusion Criteria: * Have been receiving liver transplant two years ago. * Be 18 years or older. * Treatment with immunosuppression including cyclosporine or tacrolimus. * Having a normal liver function in the last year * Not have suffered acute rejection in the last year and have no chronic rejection * Submit any significant side effects from medication immunosuppressive (hypertension, creatinine greater than 1.7 mgDl, diabetes, morbid obesity, osteoporosis, hyperlipidemia, severe hirsutism, neurotoxicity novo malignancy, etc.) * Etiology of underlying disease: alcoholic cirrhosis with or without hepatocarcinoma, metabolic diseases, amyloidotic polyneuropathy family, biliary atresia, fulminant hepatitis non-A, non-B, non-C, cirrhosis cryptogenic and generally causes no viral or autoimmune. * Patients offering sufficient guarantees of adherence to protocol * Patients who give written informed consent for participate in the study. * It is necessary that the patient meets all inclusion criteria. Exclusion Criteria: * Underlying disease of the autoimmune (primary sclerosing cholangitis, autoimmune cirrhosis, primary biliary cirrhosis) or epatocarcinoma about cirrhosis of viral or autoimmune. * Patients with chronic rejection, or acute rejection in the last year. * Patients with liver retransplantation. * patients with history of hypersensitivity or idiosyncratic reactions to methoxsalen, psoralen the compounds or any of the excipients. * patients with melanoma, cutaneous basal cell carcinoma or squamous cell coexistent. * Patients with aphakia. * Patients taking Oxoralen. * Pregnant women or nursing mothers, or adults of childbearing age not using effective contraception. * Participation in another clinical trial. * Inability to understand informed consent.